Members of the International Society of Urological Pathology (ISUP) participated in a half-day consensus conference to discuss guidelines and recommendations regarding best practice approaches to use of immunohistochemistry (IHC) in differential diagnostic situations in urologic pathology, including bladder, prostate, testis and, kidney lesions. Four working groups, selected by the ISUP leadership, identified several high-interest topics based on common or relevant challenging diagnostic situations and proposed best practice recommendations, which were discussed by the membership. The overall summary of the discussions and the consensus opinion forms the basis of a series of articles, one for each organ site. This Special Article summarizes the overall recommendations made by the four working groups. It is anticipated that this ISUP effort will be valuable to the entire practicing community in the appropriate use of IHC in diagnostic urologic pathology.
*Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
†Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD
‡Department of Pathology, Indiana University School of Medicine, Indianapolis, IN
§Department of Pathology & Immunology, Washington University School of Medicine, St Louis, MO
††Department of Pathology, New York University Medical Center
¶¶Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
∥Department of Pathology-Oncology, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden
¶Section of Pathological Anatomy, Polytechnic University of the Marche Region School of Medicine, United Hospitals, Ancona, Italy
#Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, AB
∥∥Trillium Health Partners, Mississauga and McMaster University, Hamilton, ON, Canada
**Unit of Anatomic Pathology, Department of Surgery Universidad de Cordoba, Cordoba, Spain
‡‡Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand
§§Department of Cellular Pathology, Centre for Molecular Oncology, Queen Mary University of London, London, UK
M.B.A and J.I.E. are joint first authors.
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Mahul B. Amin, MD, Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Suite 8707, Los Angeles, CA 90048 (e-mail: firstname.lastname@example.org).